The global Benign Prostatic Hyperplasia Surgical Treatment market, valued at US$11.92 billion in 2023, is forecasted to grow at a robust CAGR of 5.3%, reaching US$12.62 billion in 2024 and an ...

Background: Androgen ablation is often used in addition to low-dose-rate brachytherapy in the treatment of prostate cancer, particularly for disease with adverse features. We report a single ...

of ablation in a persistent atrial fibrillation (AF) population to show the benefit of going beyond conventional pulmonary vein isolation (PVI)-only extra-pulmonary vein procedure. Previous ...

48%, log rank p = 0.04). The safety endpoint did not differ between the groups, although the procedure and ablation time were twice as long in the Tailored arm, consistent with treatment time for ...

of ablation in a persistent atrial fibrillation (AF) population to show the benefit of going beyond conventional pulmonary vein isolation (PVI)-only extra-pulmonary vein procedure. Previous studies ...

and D90 (percent of the prescribed dose that at least 90% of the prostate received) were averaged for a random sample of 25 patients each in the androgen ablation and no-androgen ablation groups ...

A new green-light laser treatment for benign prostate disease takes only 20 minutes and reduces the risk of side-effects, including impotence and incontinence. The laser is attracted to red blood ...